Open Tender Watch
Menu v
ACCESS EN PT
← Companies Company PT

GENERIS - FARMACÊUTICA, S.A.

NIF 508107997
↓ CSV ↓ JSON
Risk Flags
A1 · Repeat Direct Award €7,043,573 118 contracts
Same supplier receives ≥2 direct awards in 36 months with cumulative value above the CCP Art. 113 §2 statutory cap
HIGH €7,043,573 118 contracts
A2 · Late Publication €18,355,902,852 10,381 contracts
Contract published to BASE more than 10 days after the signing date
LOW €18,355,902,852 10,381 contracts
A5 · Threshold Splitting €75,736,676 296 contracts
Contract value falls within 5% below a procedural threshold (€5K / €20K / €75K / €150K / €5.35M). Score: 35 · Severity: Medium.
HIGH €75,736,676 296 contracts
A6 · Low Competition €155,761 16 contracts
Only one bidder participated in a competitive procedure
MEDIUM €155,761 16 contracts
A9 · Price Overrun €13,267 6 contracts
Effective price exceeds base price by >50% (score 30) or >100% (score 55); or effective price is <50% of base (score 10, possible predatory bid or data error). Severity: Medium/High/Low.
HIGH €13,208 5 contracts
MEDIUM €59 1 contracts
A9 · Abnormal Price Reduction €23,077,439,427 7,694 contracts
Effective price exceeds base price by >50% (score 30) or >100% (score 55); or effective price is <50% of base (score 10, possible predatory bid or data error). Severity: Medium/High/Low.
LOW €23,077,439,427 7,694 contracts
C3 · Missing Mandatory Fields €4,915,950 219 contracts
CPV code, procedure type, or base price absent for the procedure type, or base price exceeds ±€1 trillion (implausible data entry). Score: 20 · Severity: Low.
LOW €4,915,950 219 contracts

Procurement Network

Aggregated links between this entity and connected counterparties

Public view excludes person-level links and tax identifiers.

Loading network…
Legend Focus entity Public body Company Anonymized individual

Contracts by Contracting Authority

1,254
€2,475,643,734
1,539
€914,742,692
274
€823,251,857
408
€813,806,885
529
€768,429,168
245
€750,719,182
451
€748,806,350
92
€744,650,011
189
€706,536,301
557
€702,514,605
549
€686,966,748
92
€685,711,811
1,075
€683,061,340
153
€671,715,271
155
€656,636,220
357
€648,520,132
155
€643,716,446
213
€640,246,758
154
€635,157,566
212
€619,921,591
Page 1 of 4 · 73 authorities
Next →

All Contracts Won

Signal: All A1 · Repeat Direct Award A2 · Late Publication A5 · Threshold Splitting A6 · Low Competition A9 · Price Overrun A9 · Abnormal Price Reduction C3 · Missing Mandatory Fields

Page 1 of 1 · 16 contracts

Fornecimento de Medicamentos do Foro Oncológico e Imunomodeladores
PT · 11258418 · Ao abrigo de acordo-qu...
A6 · Low Competition
€1,118 2025-02-28
EXCL SPMS (2023/436) GENERIS APREPITANT
PT · 11252962 · Ao abrigo de acordo-qu...
A2 · Late Publication A6 · Low Competition
€0 2025-01-01
AQUISIÇÃO DE ÁCIDO VALPRÓICO 500 MG COMP LP
PT · 11110728 · Ao abrigo de acordo-qu...
A6 · Low Competition
€642 2024-12-27
C/ BASE 2023_490
PT · 10978429 · Ao abrigo de acordo-qu...
A2 · Late Publication A6 · Low Competition
€525 2024-08-06
Aquisição de METOPROLOL 100 MG COMP
PT · 10866891 · Ajuste Direto Regime G...
A6 · Low Competition
€78 2024-08-06
Aquisição de Emtricitabina 200mg+tenofo 245mg comp OR
PT · 11038539 · Ajuste Direto Regime G...
A5 · Threshold Splitting A1 · Repeat Direct Award +2
€19,920 2024-05-23
PQ/1464/2024 - MEDICAMENTOS
PT · 10893765 · Ao abrigo de acordo-qu...
A2 · Late Publication A9 · Abnormal Price Reduction +1
€223 2024-04-17
Aquisição de GEMCITABINA 40 MG/ML SOL INJ FR 25 ML IV (AQ2023/491)
PT · 10933895 · Ao abrigo de acordo-qu...
A2 · Late Publication A6 · Low Competition
€1,883 2024-03-11
AP 10 Produtos Farmacêuticos
PT · 10581945 · Ao abrigo de acordo-qu...
A6 · Low Competition
€47 2024-02-26
61/1718/2024 - Medicamento Abacavir (ABC) 600 mg + Lamivudina (3TC) 300 mg Comp
PT · 10675841 · Ajuste Direto Regime G...
A2 · Late Publication A6 · Low Competition
€8,892 2024-02-23
Aquisição de Medicamentos do aparelho cardiovascular ao abrigo do CPA 2023/305 para a ULSASI para o ano de 2024
PT · 10566087 · Ao abrigo de acordo-qu...
A6 · Low Competition
€24,024 2024-02-18
2024000700 – Aquisição de medicamentos
PT · 10575369 · Ajuste Direto Regime G...
A6 · Low Competition
€5,832 2024-02-14
61/788/2024 - Medicamento Emtricitabina 200 mg + Tenofovir 245 mg Comp
PT · 10701721 · Ajuste Direto Regime G...
A2 · Late Publication A6 · Low Competition
€0 2024-02-13
241A000022 - Aparelho cardiovascular
PT · 11086337 · Concurso público
A2 · Late Publication A9 · Abnormal Price Reduction +1
€3,152 2024-02-12
241G000154 - AQUISIÇÃO DE AQUISIÇÃO DE METOPROLOL COMP 100 MG PARA O ANO DE 2024
PT · 10534338 · Ajuste Direto Regime G...
A6 · Low Competition
€93 2024-02-01
MEDICAMENTOS PARA A MÁQUINA DE REEMBALAGEM PROUD
PT · 10848516 · Ajuste Direto Regime G...
A2 · Late Publication A6 · Low Competition
€89,332 2024-01-19
Overview
Total Value Won
€23,189,380,103
Contracts Won
14,458
Score 513445 · CRITICAL RISK
NIF
508107997
Country
PT
Directors & Officers

Personal data is pseudonymised for public access. Authenticate with a journalist token to view full names and NIFs.

  • A.C. [P-6b27]
    Vogal
    since 2009-01-27
  • B.T. [P-5d15]
    Vogal
    since 2013-06-18
  • B.V. [P-41c8]
    Vogal
    since 2022-11-21
  • B.V. [P-41c8]
    Vogal
    since 2024-07-02
  • B.M. [P-4414]
    Vogal
    since 2013-06-18
  • D.A. [P-c2b1]
    Administrador
    since 2024-07-02
  • J.M. [P-4b91]
    Vogal
    since 2021-02-17
  • J.M. [P-4b91]
    Vogal
    since 2024-07-02
  • J.P. [P-a3d6]
    Vogal
    since 2024-07-02
  • J.M. [P-8a35]
    Presidente
    since 2013-06-18
  • J.D. [P-6dab]
    Vogal
    since 2009-01-27
  • J.L. [P-4e77]
    Vogal
    since 2009-01-27
  • J.P. [P-e7f5]
    Vogal
    since 2009-01-27
  • L.S. [P-58df]
    Presidente
    since 2021-02-17
  • L.S. [P-58df]
    Presidente
    since 2024-07-02
  • L.M. [P-cd63]
    Vogal
    since 2020-05-22
  • L.M. [P-cd63]
    Vogal
    since 2021-02-17
  • L.M. [P-cd63]
    Vogal
    since 2024-07-02
  • P.M. [P-976f]
    Administrador delegado - nomeado por cooptação
    since 2010-07-22
  • P.M. [P-976f]
    Vogal
    since 2013-06-18
  • P.P. [P-9c70]
    vogal
    since 2017-04-28
  • R.I. [P-424a]
    Vogal
    since 2021-02-17
  • R.I. [P-424a]
    Vogal
    since 2024-07-02
  • S.I. [P-c50b]
    Presidente
    since 2017-04-28
  • S.I. [P-c50b]
    Presidente
    since 2021-02-17
  • S.B. [P-2395]
    Vogal
    since 2019-05-15
  • S.B. [P-2395]
    Vogal
    since 2021-02-17
  • S.B. [P-2395]
    Vogal
    since 2024-07-02
  • V.M. [P-4ee7]
    vogal
    since 2017-04-28
  • V.M. [P-4ee7]
    Vogal
    since 2021-02-17
  • V.M. [P-4ee7]
    Presidente
    since 2024-07-02
  • C.L. [P-db3e]
    Fiscal Único
    since 2010-10-07
  • D.A. [P-c2b1]
    Fiscal Único
    since 2010-10-07
  • N.M. [P-c64f]
    Fiscal Único
    since 2009-01-19
  • P.R. [P-24a4]
    Fiscal Único
    since 2009-01-19
  • M.J. [P-082f]
    Sócio
    since 2007-09-20
  • P.M. [P-5bef]
    Sócio
    since 2007-09-20
  • A.C. [P-6b27]
    Vogal
    2013-06-18 → 2016-10-03
  • A.P. [P-d6ac]
    Vogal
    2009-01-27 → 2012-04-02
  • B.D. [P-3fbe]
    Vogal
    2009-01-27 → 2010-07-22
  • J.D. [P-6dab]
    Vogal
    2013-06-18 → 2016-12-29
  • J.P. [P-141b]
    Vogal
    2009-01-27 → 2010-07-21
  • J.L. [P-4e77]
    Presidente
    2013-06-18 → 2017-04-28
  • J.P. [P-e7f5]
    Vogal
    2013-06-18 → 2017-04-28
  • M.P. [P-7d24]
    vogal
    2017-04-28 → 2018-03-16
  • P.M. [P-976f]
    Vogal
    2017-04-28 → 2020-05-22
  • P.M. [P-63d9]
    Administrador
    2012-11-09 → 2013-03-06
  • P.M. [P-b036]
    Vogal
    2018-06-12 → 2019-05-15
  • P.P. [P-9c70]
    Vogal
    2021-02-17 → 2022-09-29
  • P.M. [P-be5a]
    Presidente
    2009-01-27 → 2010-07-21
  • N.M. [P-c64f]
    Fiscal Único
    until 2010-08-31
  • P.R. [P-24a4]
    Fiscal Único
    until 2010-08-31
Ownership & Registries

Beneficial ownership data (shareholders, directors, ultimate beneficial owners) is not yet imported. Links below open external public registries.

Registo Comercial (MJ) ↗ RCBE — Beneficial Ownership Register ↗

Full RCBE access requires judicial authentication (CJEU 2022 ruling limits public exposure).

Search in TED (EU procurement) ↗
Phase 7 — ownership layer planned